Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
NEW YORK, Feb. 16, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Cardiovascular Systems, Inc. (“Cardiovascular Systems”) (NASDAQ:CSII) between September 12, 2011 and January 21, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Central District of California. If you purchased or otherwise acquired Cardiovascular Systems securities between September 12, 2011 and January 21, 2016, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/cardiovascular-systems.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Cardiovascular Systems distributed illegal kickbacks to health care providers; (2) Cardiovascular Systems engaged in the off-label promotion of its medical devices; and (3) Cardiovascular Systems violated FDA laws and regulations in connection with its medical devices. As a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Cardiovascular Systems you have until April 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/cardiovascular-systems.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
